New approaches for improving outcomes in breast cancer in Europe
Open Access
- 1 August 2015
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 24 (4) , 321-330
Abstract
No abstract availableKeywords
Funding Information
- Astellas Pharma EMEA
This publication has 86 references indexed in Scilit:
- GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expressionNature Cell Biology, 2013
- Cancer heterogeneity: implications for targeted therapeuticsBritish Journal of Cancer, 2013
- Breast cancer survival in the US and Europe: A CONCORD high‐resolution studyInternational Journal of Cancer, 2012
- Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersBreast Cancer Research and Treatment, 2012
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- PARP Inhibitors in Cancer Therapy: Promise, Progress, and PuzzlesCancer Cell, 2011
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trialThe Lancet Oncology, 2010
- A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerBritish Journal of Cancer, 2006
- Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancerBritish Journal of Cancer, 2002